Advanced Cell Technology to Participate in the 1st International Conference on Cell Therapy and Regenerative Medicine.

WORCESTER, Mass. -- Advanced Cell Technology, Inc. (OTCBB:ACTC) will participate in the 1st International Conference on Cell Therapy and Regenerative Medicine being held on March 6-7, 2006 in Madrid, Spain. Robert Lanza, M.D., Vice President of Medical & Scientific Development, is scheduled to present on Monday, March 6th at 12:30 p.m. He will speak on "Cloning and Stem Cell Strategies in Transplantation." Dr. Lanza's slide presentation will be available on Advanced Cell Technology's website in the Conference Presentation section www.advancedcell.com/conferencepresentations.

Abstract of Dr. Lanza's Presentation

Stem cells raise the prospect of regenerating failing body parts and treating a wide range of disorders that result from tissue loss or dysfunction. Over 16 million patients worldwide suffer from neurodegenerative disorders such as Parkinson's disease, over 200 million people suffer from diabetes, and millions more from cardiovascular disease, macular degeneration, and other disorders that may one day be treatable using embryonic stem (ES) cell therapies. In addition to generating an unlimited supply of functional replacement cell types, there is also the possibility that these cells could be used to reconstitute more complex tissues and organs, including blood vessels, bone, and even entire organs such as kidneys or hearts. Techniques such as somatic cell nuclear transfer (SCNT) and parthenogenesis could potentially be used to minimize or eliminate the immune responses associated with the transplantation of these various tissues, and thus the requirement for immunosuppressive drugs and/or immunomodulatory protocols that carry the risk of a wide variety of serious and potentially life-threatening complications. The recent progress that has been made using these various ES cell strategies will be discussed, as well as the scientific challenges that remain before these techniques can be used to harness cells and tissues for human transplantation.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts. For more information about the company, please visit http://www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2005.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.